Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern; and the Department for BioMedical Research, University of Bern, Bern, Switzerland.
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern; and the Department for BioMedical Research, University of Bern, Bern, Switzerland.
Am J Pathol. 2020 Feb;190(2):412-425. doi: 10.1016/j.ajpath.2019.10.011. Epub 2019 Nov 26.
Neovascular age-related macular degeneration is one of the leading causes of blindness. Microglia and macrophages play a critical role in choroidal neovascularization (CNV) and may, therefore, be potential targets to modulate the disease course. This study evaluated the effect of the colony-stimulating factor-1 receptor inhibitor PLX5622 on experimental laser-induced CNV. A 98% reduction of retinal microglia cells was observed in the retina 1 week after initiation of PLX5622 treatment, preventing accumulation of macrophages within the laser site and leading to a reduction of leukocytes within the choroid after CNV induction. Mice treated with PLX5622 had a significantly faster decrease of the CNV lesion size, as revealed by in vivo imaging and immunohistochemistry from day 3 to day 14 compared with untreated mice. Several inflammatory modulators, such as chemokine (C-C motif) ligand 9, granulocyte-macrophage colony-stimulating factor, soluble tumor necrosis factor receptor-I, IL-1α, and matrix metallopeptidase-2, were elevated in the acute phase of the disease when microglia were ablated with PLX5622, whereas other cytokines (eg, interferon-γ, IL-4, and IL-10) were reduced. Our results suggest that colony-stimulating factor-1 receptor inhibition may be a novel therapeutic target in patients with neovascular age-related macular degeneration.
新生血管性年龄相关性黄斑变性是导致失明的主要原因之一。小胶质细胞和巨噬细胞在脉络膜新生血管(CNV)中起着关键作用,因此可能成为调节疾病进程的潜在靶点。本研究评估了集落刺激因子-1 受体抑制剂 PLX5622 对实验性激光诱导 CNV 的影响。PLX5622 治疗开始后 1 周,视网膜中小胶质细胞减少了 98%,阻止了巨噬细胞在激光部位的积聚,并导致 CNV 诱导后脉络膜中的白细胞减少。与未治疗的小鼠相比,用 PLX5622 治疗的小鼠在体内成像和免疫组织化学分析中,从第 3 天到第 14 天,CNV 病变大小的下降速度明显更快。当用 PLX5622 消融小胶质细胞时,几种炎症调节剂(如趋化因子(C-C 基序)配体 9、粒细胞-巨噬细胞集落刺激因子、可溶性肿瘤坏死因子受体-I、IL-1α 和基质金属蛋白酶-2)在疾病的急性期升高,而其他细胞因子(如干扰素-γ、IL-4 和 IL-10)则减少。我们的结果表明,集落刺激因子-1 受体抑制可能是新生血管性年龄相关性黄斑变性患者的一种新的治疗靶点。